Proteomic aptamer analysis reveals serum biomarkers associated with disease mechanisms and phenotypes of systemic sclerosis

被引:1
|
作者
Motta, Francesca [1 ,2 ]
Tonutti, Antonio [1 ,2 ]
Isailovic, Natasa [2 ]
Ceribelli, Angela [1 ,2 ]
Costanzo, Giovanni [1 ,2 ]
Rodolfi, Stefano [1 ,2 ]
Selmi, Carlo [1 ,2 ]
De Santis, Maria [1 ,2 ]
机构
[1] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy
[2] Istituti Ricovero & Cura Carattere Sci IRCCS Human, Rheumatol & Clin Immunol, Rozzano, Italy
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
connective tissue disease; interstitial lung disease; proteomics; aptamer technology; immunology; PULMONARY-FIBROSIS; MATRIX METALLOPROTEINASE-12; BRONCHOALVEOLAR LAVAGE; ANGIOPOIETIN-2; LEVELS; LEVELS CORRELATE; INTERLEUKIN-22; SCLERODERMA; LEPTIN; EXPRESSION; CLASSIFICATION;
D O I
10.3389/fimmu.2023.1246777
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundSystemic sclerosis (SSc) is an autoimmune connective tissue disease that affects multiple organs, leading to elevated morbidity and mortality with limited treatment options. The early detection of organ involvement is challenging as there is currently no serum marker available to predict the progression of SSc. The aptamer technology proteomic analysis holds the potential to correlate SSc manifestations with serum proteins up to femtomolar concentrations.MethodsThis is a two-tier study of serum samples from women with SSc (including patients with interstitial lung disease - ILD - at high-resolution CT scan) and age-matched healthy controls (HC) that were first analyzed with aptamer-based proteomic analysis for over 1300 proteins. Proposed associated proteins were validated by ELISA first in an independent cohort of patients with SSc and HC, and selected proteins subject to further validation in two additional cohorts.ResultsThe preliminary aptamer-based proteomic analysis identified 33 proteins with significantly different concentrations in SSc compared to HC sera and 9 associated with SSc-ILD, including proteins involved in extracellular matrix formation and cell-cell adhesion, angiogenesis, leukocyte recruitment, activation, and signaling. Further validations in independent cohorts ultimately confirmed the association of specific proteins with early SSc onset, specific organ involvement, and serum autoantibodies.ConclusionsOur multi-tier proteomic analysis identified serum proteins discriminating patients with SSc and HC or associated with different SSc subsets, disease duration, and manifestations, including ILD, skin involvement, esophageal disease, and autoantibodies.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Identification of novel systemic sclerosis biomarkers employing aptamer proteomic analysis
    Wermuth, Peter J.
    Piera-Velazquez, Sonsoles
    Jimenez, Sergio A.
    [J]. RHEUMATOLOGY, 2018, 57 (10) : 1698 - 1706
  • [2] SERUM PROTEOMIC BIOMARKERS DEFINE PATIENTS WITH SYSTEMIC SCLEROSIS WITH INTERSTITIAL LUNG DISEASE
    De Santis, M.
    Isailovic, N.
    Ceribelli, A.
    Motta, F.
    Vecellio, M.
    Selmi, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 152 - 152
  • [3] Serum proteomic analysis reveals novel biomarkers associated with disease activity in pediatric patients with Crohn's disease
    Werner, L.
    Weiss, B.
    Matar, M.
    Shamir, R.
    Shouval, D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I196 - I197
  • [4] Proteomic aptamer analysis reveals serum markers that characterize preclinical systemic sclerosis (SSc) patients at risk for progression toward definite SSc
    Chiara Bellocchi
    Shervin Assassi
    Marka Lyons
    Maurizio Marchini
    Chandra Mohan
    Alessandro Santaniello
    Lorenzo Beretta
    [J]. Arthritis Research & Therapy, 25
  • [5] Proteomic aptamer analysis reveals serum markers that characterize preclinical systemic sclerosis (SSc) patients at risk for progression toward definite SSc
    Bellocchi, Chiara
    Assassi, Shervin
    Lyons, Marka
    Marchini, Maurizio
    Mohan, Chandra
    Santaniello, Alessandro
    Beretta, Lorenzo
    [J]. ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [6] Serum metabolomic profiling reveals potential biomarkers in systemic sclerosis
    Guo, Muyao
    Liu, Di
    Jiang, Yu
    Chen, Weilin
    Zhao, Lijuan
    Bao, Ding
    Li, Yisha
    Distler, Jorg H. W.
    Zhu, Honglin
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2023, 144
  • [7] Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
    Meier, C.
    Freiburghaus, K.
    Bovet, C.
    Schniering, J.
    Allanore, Y.
    Distler, O.
    Nakas, C.
    Maurer, B.
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [8] SERUM METABOLITES AS BIOMARKERS IN SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
    Meier, C.
    Freiburghaus, K.
    Bovet, C.
    Schniering, J.
    Distler, O.
    Nakas, C.
    Maurer, B.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1108 - 1108
  • [9] Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease
    C. Meier
    K. Freiburghaus
    C. Bovet
    J. Schniering
    Y. Allanore
    O. Distler
    C. Nakas
    B. Maurer
    [J]. Scientific Reports, 10
  • [10] Proteomic biomarkers for survival in systemic sclerosis-associated pulmonary hypertension
    Mismetti, Valentine
    Delavenne, Xavier
    Montani, David
    Bezzeghoud, Souad
    Delezay, Olivier
    Hodin, Sophie
    Launay, David
    Marchand-Adam, Sylvain
    Nunes, Hilario
    Ollier, Edouard
    Reynaud-Gaubert, Martine
    Pastre, Jean
    Traclet, Julie
    Quetant, Sebastien
    Zeghmar, Sabrina
    Bertoletti, Laurent
    Cottin, Vincent
    [J]. RESPIRATORY RESEARCH, 2023, 24 (01)